Key result
Oral P2Y12 inhibitor pretreatment before PCI fails to reduce 30-day mortality in STEMI.
Why the study?
Pretreatment with oral P2Y12 inhibitors is standard practice for STEMI patients undergoing PCI, but its efficacy and safety remain unclear.
Does pretreatment with oral P2Y12 inhibitors reduce all-cause mortality, myocardial infarction, or major bleeding in STEMI patients undergoing PCI?
Meta-Analysis (n=70,465)
Does pretreatment with oral P2Y12 inhibitors reduce all-cause mortality, myocardial infarction, or major bleeding in STEMI patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
Routine pretreatment with oral P2Y12 inhibitors before PCI in STEMI patients does not significantly improve 30-day mortality, MI, or major bleeding, although pre-hospital administration may reduce reinfarction.
BACKGROUND: Pretreatment with oral P2Y12 inhibitors is a standard practice for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). However, the efficacy and safety of P2Y12 inhibitors pretreatment remain unclear. OBJECTIVES: We conducted a meta-analysis to investigate the impact of P2Y12 inhibitor pretreatment on thrombotic and hemorrhagic endpoints in STEMI patients. METHODS: We searched multiple databases for studies that compared P2Y12 inhibitor pretreatment with no pretreatment in STEMI patients and reported endpoints of interest. Random effects model was used for the meta-analysis. RESULTS: Our meta-analysis included 3 randomized controlled trials and 14 observational studies, comprising 70,465 patients assigned to either P2Y12 inhibitor pretreatment (50,328 patients) or no pretreatment (20,137 patients). Compared to no pretreatment, P2Y12 inhibitor pretreatment did not result in significant reductions in all-cause mortality (risk ratio [RR] 0.73; 95% confidence interval [CI]: 0.52-1.03; p = 0.07), myocardial infarction (RR 0.75; 95% CI: 0.53-1.07; p = 0.11), or major bleeding (RR 0.80; 95% CI: 0.56-1.16; p = 0.22) at 30 days. However, our subgroup analysis revealed that P2Y12 inhibitor pretreatment administered in the pre-hospital setting was associated with a significant reduction in the incidence of myocardial infarction compared to no pretreatment (RR 0.73; 95% CI: 0.56-0.91; p < 0.01). CONCLUSION: Our analysis suggests that pretreatment with oral P2Y12 inhibitors before PCI in patients with STEMI was not associated with reduced all-cause mortality, myocardial infarction, or major bleeding. However, pretreatment with P2Y12 inhibitors in the pre-hospital setting appears to be beneficial in reducing reinfarction.
No takes yet. Share an insight, caveat, or question.
Gewehr et al. (2023) conducted a meta-analysis in ST-elevation myocardial infarction (STEMI) (n=70,465). Oral P2Y12 inhibitor pretreatment vs. No pretreatment was evaluated on All-cause mortality at 30 days (RR 0.73, 95% CI 0.52-1.03, p=0.07). Pretreatment with oral P2Y12 inhibitors before PCI in STEMI patients did not reduce 30-day all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: